Clinical Trial Update: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing daily oral orforglipron (LY3502970) to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiova…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Chronic Kidney Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes, Obesity | Phase 3 | Status: COMPLETED